Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1006 participants.

Also called NCT03891277

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,006 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03891277
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03891277. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-01 (actual); primary completion 2021-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)
Acronym
FAVORITE
Condition
Vascular Cognitive Impairment
Condition
Dementia, Vascular
Condition
Iron-deficiency
Condition
Cerebral Infarction
Intervention (Drug)
Ferrous succinate
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct03891277
Content hash
aaaa1d45fdd43fde0c427bf850d1741569752eecce797db34e764f0054168c50